Qinlong Li1, Quanlin Li2, Jill Nuccio3, Chunyan Liu1, Peng Duan1, Ruoxiang Wang1, Lawrence W Jones3, Leland W K Chung1,4, Haiyen E Zhau1. 1. Department of Medicine, Uro-Oncology Research Program, Los Angeles, California. 2. Biostatistics and Bioinformatics, Cedars-Sinai Medical Center, Los Angeles, California. 3. Urological Research, Huntington Medical Research Institutes, Huntington Memorial Hospital, Pasadena, California. 4. Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California.
Abstract
BACKGROUND: We previously reported that the activation of RANK and c-Met signaling components in both experimental mouse models and human prostate cancer (PC) specimens predicts bone metastatic potential and PC patient survival. This study addresses whether a population of metastasis-initiating cells (MICs) known to express a stronger RANKL, phosphorylated c-Met (p-c-Met), and neuropilin-1 (NRP1) signaling network than bystander or dormant cells (BDCs) can be detected in PC tissues from patients subjected to transurethral resection of the prostate (TURP) for urinary obstruction prior to the diagnosis of PC with or without prior hormonal manipulation, and whether the relative abundance of MICs over BDCs could predict castration-resistant progression and PC patient survival. METHODS: We employed a multiplexed quantum-dot labeling (mQDL) protocol to detect and quantify MICs and BDCs at the single cell level in TURP tissues obtained from 44 PC patients with documented overall survival and castration resistance status. RESULTS: PC tissues with a higher number of MICs and an activated RANK signaling network, including increased expression of RANKL, p-c-Met, and NRP1 compared to BDCs, were found to correlate with the development of castration resistance and overall survival. CONCLUSIONS: The assessment of PC cells with MIC and BDC phenotypes in primary PC tissues from hormone-naïve patients can predict the progression to castration resistance and the overall survival of PC patients.
BACKGROUND: We previously reported that the activation of RANK and c-Met signaling components in both experimental mouse models and humanprostate cancer (PC) specimens predicts bone metastatic potential and PC patient survival. This study addresses whether a population of metastasis-initiating cells (MICs) known to express a stronger RANKL, phosphorylated c-Met (p-c-Met), and neuropilin-1 (NRP1) signaling network than bystander or dormant cells (BDCs) can be detected in PC tissues from patients subjected to transurethral resection of the prostate (TURP) for urinary obstruction prior to the diagnosis of PC with or without prior hormonal manipulation, and whether the relative abundance of MICs over BDCs could predict castration-resistant progression and PC patient survival. METHODS: We employed a multiplexed quantum-dot labeling (mQDL) protocol to detect and quantify MICs and BDCs at the single cell level in TURP tissues obtained from 44 PC patients with documented overall survival and castration resistance status. RESULTS: PC tissues with a higher number of MICs and an activated RANK signaling network, including increased expression of RANKL, p-c-Met, and NRP1 compared to BDCs, were found to correlate with the development of castration resistance and overall survival. CONCLUSIONS: The assessment of PC cells with MIC and BDC phenotypes in primary PC tissues from hormone-naïve patients can predict the progression to castration resistance and the overall survival of PC patients.
Authors: Wen-Chin Huang; Zhihui Xie; Hiroyuki Konaka; Jaro Sodek; Haiyen E Zhau; Leland W K Chung Journal: Cancer Res Date: 2005-03-15 Impact factor: 12.701
Authors: Daniel Schramek; Andreas Leibbrandt; Verena Sigl; Lukas Kenner; John A Pospisilik; Heather J Lee; Reiko Hanada; Purna A Joshi; Antonios Aliprantis; Laurie Glimcher; Manolis Pasparakis; Rama Khokha; Christopher J Ormandy; Martin Widschwendter; Georg Schett; Josef M Penninger Journal: Nature Date: 2010-09-29 Impact factor: 49.962
Authors: Vincent Duheron; Estelle Hess; Monique Duval; Marion Decossas; Beatriz Castaneda; Jennifer E Klöpper; Leonela Amoasii; Jean-Baptiste Barbaroux; Ifor R Williams; Hideo Yagita; Josef Penninger; Yongwon Choi; Frédéric Lézot; Richard Groves; Ralf Paus; Christopher G Mueller Journal: Proc Natl Acad Sci U S A Date: 2011-03-14 Impact factor: 11.205
Authors: Brenda K Edwards; Anne-Michelle Noone; Angela B Mariotto; Edgar P Simard; Francis P Boscoe; S Jane Henley; Ahmedin Jemal; Hyunsoon Cho; Robert N Anderson; Betsy A Kohler; Christie R Eheman; Elizabeth M Ward Journal: Cancer Date: 2013-12-16 Impact factor: 6.860
Authors: T L Burgess; Y Qian; S Kaufman; B D Ring; G Van; C Capparelli; M Kelley; H Hsu; W J Boyle; C R Dunstan; S Hu; D L Lacey Journal: J Cell Biol Date: 1999-05-03 Impact factor: 10.539
Authors: Gina Chia-Yi Chu; Haiyen E Zhau; Ruoxiang Wang; André Rogatko; Xu Feng; Majd Zayzafoon; Youhua Liu; Mary C Farach-Carson; Sungyong You; Jayoung Kim; Michael R Freeman; Leland W K Chung Journal: Endocr Relat Cancer Date: 2014-03-04 Impact factor: 5.678
Authors: Qinlong Li; Lijuan Yin; Lawrence W Jones; Gina C-Y Chu; Jason B-Y Wu; Jen-Ming Huang; Quanlin Li; Sungyong You; Jayoung Kim; Yi-Tsung Lu; Stefan Mrdenovic; Ruoxiang Wang; Michael R Freeman; Isla Garraway; Michael S Lewis; Leland W K Chung; Haiyen E Zhau Journal: Oncotarget Date: 2016-12-20
Authors: Saber H Saber; Hamdy E A Ali; Rofaida Gaballa; Mohamed Gaballah; Hamed I Ali; Mourad Zerfaoui; Zakaria Y Abd Elmageed Journal: Cells Date: 2020-02-28 Impact factor: 6.600
Authors: Catherine A Sánchez; Eliana I Andahur; Rodrigo Valenzuela; Enrique A Castellón; Juan A Fullá; Christian G Ramos; Juan C Triviño Journal: Oncotarget Date: 2016-01-26